In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare ...

Moderna (NASDAQ:MRNA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by stock analysts at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Financially, Barclays noted that Moderna’s revenue declined sharply. Fourth-quarter SpikeVax sales came in at $923 million, below Barclays’ estimate of $1.087 billion, and total 2024 product revenue ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

The health care sector is likely reacting to the uncertainty created by the effect of federal budget cuts now being ...

The e-commerce company's Hong Kong stock rallied 6.3% after Bloomberg and Reuters reported that Chinese President Xi Jinping would meet with Alibaba co-founder Jack Ma and other business leaders.

The Dow fell and the Nasdaq Composite rose Nasdaq Friday as the stock market reacted to news of delays to President Donald Trump's reciprocal tariffs.